Table 3

Details of the unmatched in situ hybridisation cases
Case ID
 PathVysion
 PharmDx™
 INFORM
 CISH

HER2 signals per nucleus
 CEP17 signals per nucleus
 Ratio
 HER2 signals per nucleus
 CEP17 signals per nucleus
 Ratio
 HER2 signals per nucleus
 HER2 signals per nucleus
20
 5.6
 5.3 (P)
 1.1
 6.2
 4.0 (P)
 1.6
 4.9
 6.4
21
 2.2
 2.5
 0.9
 5.1
 3.3 (P)
 1.6
 5.6
 5.6
22
 -
 -
 -
 4.5
 2.0
 2.3
 3.8
 3.6
24
 2.6
 2.5
 1.0
 3.3
 2.6
 1.2
 4.3
 Clusters
25
 3.7
 3.8 (P)
 1.0
 6.2
 4.0 (P)
 1.6
 7.7
 5.5
26
 4.4
 2.8
 1.6
 6.1
 4.2 (P)
 1.5
 5.3
 6.6
27
 3.4
 2.2
 1.5
 3.8
 2.4
 1.6
 4.8
 3.7
28
 3.8
 3.7 (P)
 1.0
 4.0
 3.4 (P)
 1.2
 5.7
 4.9
29
 2.0
 2.0
 1.0
 3.5
 2.0
 1.7
 4.4
 3.6
30
 4.6
 3.3 (P)
 1.4
 5.7
 3.7 (P)
 1.5
 5.5
 3.4
32
 2.0
 2.5
 0.8
 2.0
 2.0
 1.0
 4.2
 4.9
33
 5.6
 5.0 (P)
 1.1
 5.2
 3.5 (P)
 1.5
 4.5
 5.7
34
 3.3
 2.2
 1.5
 3.3
 2.1
 1.6
 4.1
 2.5
35
 3.1
 3.5 (P)
 0.9
 2.8
 2.7
 1.0
 4.2
 3.3

HER2, human epidermal growth factor receptor 2; CEP17, chromosome enumeration probe 17; P, polysomy; CISH, chromogenic in situ hybridisation.

Cayre et al. Breast Cancer Research 2007 9:R64   doi:10.1186/bcr1770

Open Data